Latest Clinical Data News

Anatara Lifesciences' compound AOC shows statistically significant pre-clinical effects in weight control, prompting consideration of an open label trial. The company maintains tight financial discipline while advancing its gastrointestinal health project GaRP towards publication.

Chimeric Therapeutics has reported encouraging Phase 1/2 trial results for its CHM CDH17 CAR-T therapy, alongside a 60% complete response rate in its AML NK cell trial. However, cash reserves remain tight at $0.8 million with a strategic review underway.

Radiopharm Theranostics reported a 93% success rate in its Phase 2b trial of RAD 101 for brain metastases imaging and aims to start a Phase 3 trial in Q4 2026. The company also raised $12.5 million post-quarter to support ongoing development.

Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.

AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.

Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.

Adherium Limited has posted a fourth consecutive quarter of record remote patient monitoring revenue, driven by growing device activations and strong clinical evidence from the iCARE study, positioning the company for expanded value-based care contracts in the US.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Imugene's azer-cel therapy shows a third patient response in the BTKi combination cohort of its Phase 1b trial, while CEO Leslie Chong steps down after nearly 11 years, prompting a leadership search.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.

Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.